Microsoft introduced Microsoft Discovery, an enterprise platform designed to support AI-native biotech research workflows, featuring agentic automation, graph-based knowledge systems and high-performance computing infrastructure. The platform was built for regulated scientific environments with support for tenant deployment, provenance tracking, secure model fine-tuning and integration with proprietary datasets and tools.
Microsoft emphasized operational priorities including scalable orchestration for compute-intensive workloads, reproducibility for scientific evidence generation and confidential compute architectures that allow models to run inside partner cloud environments. The company also highlighted Azure’s independent GxP supplier audit as validation for regulated workloads and enterprise compliance readiness.
For biotech startups and enterprise partners, Microsoft Discovery aims to reduce infrastructure friction while accelerating AI-driven experimentation, collaboration and evidence generation, reflecting broader demand for secure, auditable AI systems in regulated life-sciences research.
Image Credit: Microsoft